We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04439071




Registration number
NCT04439071
Ethics application status
Date submitted
17/06/2020
Date registered
19/06/2020
Date last updated
8/04/2021

Titles & IDs
Public title
A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)
Scientific title
Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)
Secondary ID [1] 0 0
2020-001872-13
Secondary ID [2] 0 0
PTC299-VIR-015-COV19
Universal Trial Number (UTN)
Trial acronym
FITE19
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pneumonia 0 0
COVID-19 0 0
Coronavirus 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PTC299
Other interventions - SOC
Treatment: Drugs - Placebo

Experimental: PTC299 + Standard of Care (SOC) - Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.
SOC will also be administered according to local, written policies or guidelines.

Placebo Comparator: Placebo + SOC - Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.
SOC will also be administered according to local, written policies or guidelines.


Treatment: Drugs: PTC299
Oral tablets

Other interventions: SOC
As defined per local written policies or guidelines.

Treatment: Drugs: Placebo
Oral tablets

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time from Randomization to Respiratory Improvement - Respiratory improvement is defined as sustained peripheral oxygen saturation (SpO2) =94% on room air.
Timepoint [1] 0 0
up to Day 28
Secondary outcome [1] 0 0
Percentage of Participants Requiring Invasive Ventilation
Timepoint [1] 0 0
up to Day 28
Secondary outcome [2] 0 0
Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline
Timepoint [2] 0 0
up to Day 28
Secondary outcome [3] 0 0
Time from Randomization to Defervescence in Participants Presenting With Fever at Enrollment (Temperature of =37.6? Axilla, =38.0? Oral, or =38.6°C Tympanic or Rectal)
Timepoint [3] 0 0
up to Day 28
Secondary outcome [4] 0 0
Time from Randomization to Respiratory Rate = 24 Breaths per Minute on Room Air
Timepoint [4] 0 0
up to Day 28
Secondary outcome [5] 0 0
Time from Randomization to Cough Reported as Mild or Absent - Cough will be rated on a scale of severe, moderate, mild, absent, in those with cough at enrollment rated severe or moderate.
Timepoint [5] 0 0
up to Day 28
Secondary outcome [6] 0 0
Time from Randomization to Dyspnea Reported as Mild or Absent - Dyspnea will be rated on a scale of severe, moderate, mild, absent, in those with dyspnea at enrollment rated as severe or moderate.
Timepoint [6] 0 0
up to Day 28
Secondary outcome [7] 0 0
Reduction of Immune Responses
Timepoint [7] 0 0
up to Day 28
Secondary outcome [8] 0 0
Reduction in Viral Load
Timepoint [8] 0 0
up to Day 28
Secondary outcome [9] 0 0
Duration of Hospitalization
Timepoint [9] 0 0
up to Day 28
Secondary outcome [10] 0 0
Number of Mortalities
Timepoint [10] 0 0
Day 28
Secondary outcome [11] 0 0
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Timepoint [11] 0 0
up to Day 28

Eligibility
Key inclusion criteria
- Signed and dated informed consent document(s).

- Agrees to the collection of nasopharyngeal swabs and venous blood and all other
protocol-specified procedures.

- Male or non-pregnant female adult =18 years of age at time of enrollment.

- Hospitalized and has laboratory-confirmed infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2).

- Symptom onset was =10 days prior to screening.

- Has oxygen saturation SpO2 <94% on room air.

- Has at least one of a respiratory rate >24 breaths/minute or cough.

- Lung involvement as confirmed by radiographic infiltrates observed on imaging (chest
X-ray, computed tomography (CT) scan, or an equivalent test).

- Women of childbearing potential (as defined in [CTFG 2014]) must have a negative
pregnancy test at screening and agree to abstinence or the use at least one of the
following highly effective forms of contraception (with a failure rate of <1% per year
when used consistently and correctly). Contraception or abstinence must be continued
for the duration of the study following discharge from the hospital, and for up to 50
days after the last dose of study drug:

i) combined (estrogen and progestogen containing) hormonal contraception associated
with inhibition of ovulation: oral, intravaginal, and transdermal ii) progestogen-only
hormonal contraception associated with inhibition of ovulation: oral, injectable, and
implantable iii) intrauterine device iv) intrauterine hormone-releasing system v)
vasectomized partner with confirmed azoospermia All females will be considered of
childbearing potential unless they are postmenopausal (at least 12 months consecutive
amenorrhea in the appropriate age group without other known or suspected cause) or
have been sterilized surgically (for example, bilateral tubal ligation, hysterectomy,
bilateral oophorectomy).

- Men sexually active with women of childbearing potential who have not had a vasectomy
must agree to use a barrier method of birth control during the study following
discharge from the hospital and for up to 50 days after the last dose of study drug.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Requires mechanical ventilation.

- Current participation in any other interventional study.

- Alanine transaminase/aspartate transaminase levels =3 times the upper limit of normal
(×ULN) or total bilirubin (Tbili) =2×ULN.

- Lymphocyte count <500 lymphocytes/microliter (µL) or hemoglobin <11 grams/deciliter
(g/dL).

- Stage 4 severe chronic kidney disease or requiring dialysis (that is, estimated
glomerular filtration rate <30).

- Any other condition, that in the opinion of the Investigator, may be cause to exclude
the participant from the study.

- Use of steroids (except dexamethasone), sensitive CYP2D6 substrates, CYP2C inducers,
IL-6 neutralizing antibodies, IL-6 receptor inhibitors, or any investigational
therapy.

- Pregnancy or breast feeding.

- Anticipated transfer to another hospital which is not a study site within 72 hours.

- Known allergy to PTC299 or excipients.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment hospital [2] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [3] 0 0
Sunshine Hospital - St. Albans
Recruitment postcode(s) [1] 0 0
02145 - Westmead
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
03021 - St. Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
South Carolina
Country [8] 0 0
Belgium
State/province [8] 0 0
Brussels
Country [9] 0 0
Belgium
State/province [9] 0 0
Ottignies
Country [10] 0 0
Brazil
State/province [10] 0 0
MG
Country [11] 0 0
Brazil
State/province [11] 0 0
SP
Country [12] 0 0
Mexico
State/province [12] 0 0
Cdmx
Country [13] 0 0
Mexico
State/province [13] 0 0
Guanajuato
Country [14] 0 0
Mexico
State/province [14] 0 0
Nuevo León
Country [15] 0 0
Portugal
State/province [15] 0 0
Lisboa
Country [16] 0 0
Portugal
State/province [16] 0 0
Santa Maria da Feira
Country [17] 0 0
Portugal
State/province [17] 0 0
Vila Nova de Gaia
Country [18] 0 0
Spain
State/province [18] 0 0
Barcelona
Country [19] 0 0
Spain
State/province [19] 0 0
Madrid
Country [20] 0 0
Spain
State/province [20] 0 0
San Sebastián de los Reyes

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
PTC Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult
participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
Trial website
https://clinicaltrials.gov/show/NCT04439071
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Quintus Ngumah, OD, PhD
Address 0 0
PTC Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Patient Advocacy
Address 0 0
Country 0 0
Phone 0 0
1-866-562-4620
Fax 0 0
Email 0 0
medinfo@ptcbio.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04439071